ClinicalTrials.Veeva

Menu

Effect of Stellate Ganglion Block on Pharyngeal Dysphagia After Cerebralvascular Accident

Z

Zeng Changhao

Status

Completed

Conditions

Dysphagia

Treatments

Drug: Lidocaine hydrochloride
Behavioral: comprehensive rehabilitation

Study type

Interventional

Funder types

Other

Identifiers

NCT06249464
SGB for stroke old

Details and patient eligibility

About

This was a multicenter randomized controlled study. 66 post-stroke patients with pharyngeal dysphagia were randomly allocated to the observation group (n=33) or the control group (n=33). Both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. Besides, the observation group additionally underwent the stellate ganglion block (SGB). At admission and after 20-day treatment, Kubota water swallowing test, video fluoroscopic swallowing study (VFSS), and Rosenbek penetration-aspiration scale (PAS) were used to assess swallowing function.

Full description

Dysphagia is a frequent and potentially serious complication of stroke. However, there is no effective measure for the treatment of pharyngeal dysphagia in stroke patients. This study aims to explore the efficacy of stellate ganglion block in post-stroke pharyngeal dysphagic patients who received comprehensive rehabilitation. This was a multicenter randomized controlled study. 66 post-stroke patients with pharyngeal dysphagia were randomly allocated to the observation group (n=33) or the control group (n=33). Both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. Besides, the observation group additionally underwent the stellate ganglion block (SGB). At admission and after 20-day treatment, Kubota water swallowing test, video fluoroscopic swallowing study (VFSS), and Rosenbek penetration-aspiration scale (PAS) were used to assess swallowing function.

Enrollment

65 patients

Sex

All

Ages

30 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 30 and 80 years;
  • New-onset stroke;
  • The course of disease between 1 to 6 months;
  • With pharyngeal dysphagia;
  • Stable vital signs;
  • Voluntary participation in the study.

Exclusion criteria

  • Allergy to Lidocaine injection or vitamin B12 injection;
  • Severe cognitive impairment;
  • Coagulation disorders;
  • Severe dysfunction of organs including heart, lungs, kidney, liver, etc.;
  • Complicated with other neurological diseases;
  • Dysphagia caused by other diseases or reasons.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

65 participants in 2 patient groups

Stellate Ganglion Block group
Experimental group
Description:
Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
Treatment:
Behavioral: comprehensive rehabilitation
Drug: Lidocaine hydrochloride
Routine treatment group
Active Comparator group
Description:
Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
Treatment:
Behavioral: comprehensive rehabilitation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems